The new facility will produce plasma-derived products
Singapore: Plasma-based biopharmaceutical company, China Biologic Products' subsidiary firm, Shandong Taibang Biological Products has received Good Manufacturing Practices certification from the China Food and Drug Administration for its new coagulation factor production facility.
This new facility will primarily be used to produce plasma-derived prothrombin complex concentrate, factor VIII and various other coagulation factors in the pipeline. This new facility has the capability to produce multiple coagulation factors concurrently and on a larger scale compared with the Company's existing production facilities.The Company expects to begin commercial production at this new facility immediately.
Mr David (Xiaoying) Gao, chairman and chief executive officer, China Biologic, commented, "We are pleased to receive our GMP certificate and be able to launch operations in our newest production facility. Once operational, this new facility will increase our overall production capacity and enable us to continue to meet the growing demand for plasma-based products in China. We anticipate that our new facility will have a positive impact on our 2015 financial results."
